Abstract:Objective To evaluate a strategy of using TF siRNA loaded in a novel external stent prepared by hybrid uhrafine fibrous membrane consisting of PLGA/Chitosan nannoparticles as a therapy for vein graft disease.Methods Hybrid ultrafine fibrous membranes consisting of PLGA/Chitosan nannoparticles were fabricated via a specially designed electrospinning setup. After soaking in chloroform to dissolve PLGA. the amount of chitosan in the hybrid membranes was determined. The water uptake of the hybrid ultrafine fibrous membranes was investigated by incubation in phosphate buffer solution.Right jugular vein-carotid artery interposition grafting models in Spragne-Dawley rats were randomly divided into five groups:Group A(external stent consisting of PLGA/CS-TFsiRNA nanoparticles),Group B(external stent consisting of PLGA/CS.Stealth~(TM) RNAi negative control nanoparticles),Group C(external stent consisting of PLGA/CS blank nanoparticles),Group D(external stent consisting of PLGA),Group E(without perivenous extereal stent).BLOCK-iT~(TM) Fluorescent Oligo was used to confirm its stability and successful transfer into the vein graft wall.The vein grafts were harvested at 1,3,7,14,28 d after operation,respectively.The TF protein expression of vein grafts was analyzed by Westem blot and immunochemistry at 1,3,7 d after operation,respectively.The expression of proliferating cell nuclear antigen(PCNA)was identified by immunochemistry methods. The thickness of neointima at 28 d was calculatod by computer imaging analysis system. Results The PLGA and CS amount in PLGA/Chitosan nannoparticles membranes could be well controlled by adjusting the flow rate for electrospinning of PLGA and chitosan nannoparticles, respectively. Because of the introduction of chitosan,which is a naturally hydrophilic polymer,the hybrid membranes exhibited good water absorption properties.BIOCK-iT~(TM) Fluorescent Oligo could be detected in the graft wall even 12days after operation.The expression of TF protein in Group A Was significantly less than that in control groups at 3 d after operation(P＜0.05,0.40±0.03 vs 0.75 ±0.01、0.75 ±0.05、0.77 ±0.07)and at 7 d after operation(P＜0.05,0.30±0.03 vs 0.84±0.05、0.86±0.06、0.85±0.06).The expression of PCNA in Group A decreased significantly in comparison with control groups at 14 d after operation(P＜0.01,13.0%±2.6%vs 25.0%±2.8%、24.2%±3.9%、24.0%±4.1%、44.8%±3.7%).The thickness of neointima at 28 d after grafting in Group A Was significantly less than the untreated group(P＜0.01,18.8μm±2.9 μm vs 38.7 μm±5.0μm、37.3μm ±3.6 μm、37.2μm±2.6μm、67.5μm±4.8μm).Conclusion rrhe hovel external stent prepared by hybrid uhrafine fibrous membrane consisting of PLGA/Chitosan nannoparticles inhibits early neointima formation in rat vein grafts.This strategy may be a practicable and promising form of gene delivery against vein graft failure.

Inhibitory Effect of TLR4 Gene Silencing on Intimal Hyperplasia of Vein Grafting

Preventing Intimal Thickening of Vein Grafts in Vein Artery Bypass Using STAT-3 Sirna

Local Tansfection of Antisense Transforming Growth Factor-Β1 Carried by Nanoparticles Inhibits Intimal Hyperplasia in Autogenous Vein Grafts in Rats

Lack of Interleukin-1 Signaling Results in Perturbed Early Vein Graft Wall Adaptations.

Inhibitory effect of Psilencer1.0-U6-siRNA-stat3 on neointima hyperplasia of vein graft after arterial bypass

MicroRNA-146a sponge therapy suppresses neointimal formation in rat vein grafts.

Inhibition of intimal hyperplasia in murine aortic allografts by administration of a small-molecule TLR4 inhibitor TAK-242

Effects of the Different-Sized External Stents on Vein Graft Intimal Hyperplasia and Inflammation

Experimental Study of Egr-1,PDGF-B and TGF-β_1 Genes in Autogenous Vein Graft

Effect of bFGF antisense oligonucleotides on intimal hyperplasia of vein autografts of rats

MicroRNA-365 Promotes the Contractile Phenotype of Venous Smooth Muscle Cells and Inhibits Neointimal Formation in Rat Vein Grafts.

[Role of toll like receptor 4 in low shear stress-induced intimal hyperplasia]

Controlled release of siRNA nanoparticles loaded in a novel external stent prepared by emulsion electrospinning attenuates neointima hyperplasia in vein grafts

Local Gene Transfer of Tissue Inhibitor of Metalloproteinase-2 Influences Vein Graft Remodeling in a Mouse Model

MicroRNA-221 sponge therapy attenuates neointimal hyperplasia and improves blood flows in vein grafts

Arterial Cyclic Stretch Regulates Lamtor1 and Promotes Neointimal Hyperplasia Via Circslc8a1/mir-20A-5p Axis in Vein Grafts.

[To Study the Effects of Local Co-Transfection Vascular Endothelial Growth Factor165 and Tissue-Type Plasminogen Activator Genes on Inhibiting Intimal Hyperplasia after Operation Injury Artery in Rabbits].

Gene Transfer of Calcitonin Gene-Related Peptide Inhibits Macrophages and Inflammatory Mediators in Vein Graft Disease

Empirical Study of Transfecting Early Growth Response Gene‐1 DNA Enzyme to Prevent Intimal Hyperlasia of Autogenous Vein Graft in Rats

Early Growth Response Gene-1 Decoy Oligonucleotides Inhibit Vascular Smooth Muscle Cell Proliferation and Neointimal Hyperplasia of Autogenous Vein Graft in Rabbits.

WITHDRAWN: Smooth Muscle Cell-Specific Knockout of Interferon Gamma (Ifn-Γ) Receptor Attenuates Intimal Hyperplasia Via STAT1-KLF4 Activation